全髋或全膝关节置换术后利伐沙班后阿司匹林与单用阿司匹林的比较
这项多中心、双盲、随机对照试验纳入5429例全髋或全膝关节置换术患者,比较术后前5天每日一次81 mg阿司匹林或10 mg口服利伐沙班,之后所有患者继续每日81 mg阿司匹林(膝关节置换额外9天,髋关节置换额外30天)。90天随访症状性静脉血栓栓塞(近端深静脉血栓或肺栓塞)在单用阿司匹林组0.48%、利伐沙班后阿司匹林组0.45%(风险差0.02个百分点,95%CI -0.34至0.39,非劣效P<0.001)。大出血或临床相关非大出血单用阿司匹林组1.66%、利伐沙班后阿司匹林组2.04%(风险差-0.38%,95%CI -1.11至0.34)。
要点
- 全髋/膝关节置换术后单用阿司匹林(81 mg每日一次)预防症状性VTE不劣于利伐沙班后阿司匹林,非劣效界值0.7个百分点。
- 主要疗效终点(近端DVT或PE)发生率:单用阿司匹林0.48% vs 利伐沙班后阿司匹林0.45%,风险差0.02个百分点(95%CI -0.34至0.39)。
- 主要安全终点(大出血或临床相关非大出血):单用阿司匹林1.66% vs 利伐沙班后阿司匹林2.04%,风险差-0.38%(95%CI -1.11至0.34)。
- 适用人群为接受全髋或全膝关节置换术的患者,研究排除了哪些人群原文未提及。
适用人群与场景
- 接受全髋或全膝关节置换术的患者,多中心随机对照试验纳入5429例。
诊断标准与关键阈值
- 主要疗效终点为90天内症状性静脉血栓栓塞,包括近端深静脉血栓或肺栓塞。
- 主要安全终点为出血并发症,包括大出血或临床相关非大出血。
- 非劣效界值为0.7个百分点。
处置流程与药物剂量
- 第一步:全髋或全膝关节置换术后前5天,每日一次给予81 mg阿司匹林或10 mg口服利伐沙班。
- 第三步:随访90天评估症状性静脉血栓栓塞和出血并发症。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:多中心、双盲、随机对照试验,样本量5429例,随机分为单用阿司匹林组2718例和利伐沙班后阿司匹林组2647例。
- 主要疗效终点:症状性VTE单用阿司匹林组13/2718(0.48%),利伐沙班后阿司匹林组12/2647(0.45%),风险差0.02个百分点(95%CI -0.34至0.39),非劣效P<0.001。
- 主要安全终点:大出血或临床相关非大出血单用阿司匹林组45/2718(1.66%),利伐沙班后阿司匹林组54/2647(2.04%),风险差-0.38%(95%CI -1.11至0.34)。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机对照试验。
- 局限:原文未提及。
对床旁实践的改变
- 对于全髋或全膝关节置换术后患者,单用阿司匹林(81 mg每日一次)可作为利伐沙班后阿司匹林策略的替代选择,不增加症状性VTE风险。
- 出血事件无临床相关差异,但需注意研究方案中阿司匹林剂量为81 mg每日一次,疗程按手术类型不同。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Aspirin after an initial short course of rivaroxaban has been shown to be safe and effective for the prevention of venous thromboembolism after total hip or total knee arthroplasty, but uncertainty remains about the use of aspirin alone.
METHODS: In this multicenter, double-blind, randomized, controlled trial, we assigned patients to receive once-daily thromboprophylaxis with either 81 mg of aspirin or 10 mg of oral rivaroxaban for the first 5 days after total hip or total knee arthroplasty. All the patients then received further thromboprophylaxis with 81 mg of aspirin daily for 9 additional days after knee arthroplasty and for 30 additional days after hip arthroplasty. Patients were followed for 90 days for symptomatic venous thromboembolism, which consisted of either proximal deep-vein thrombosis or pulmonary embolism (primary effectiveness outcome), and for bleeding complications (primary safety outcome). The noninferiority margin for aspirin alone as compared with rivaroxaban-aspirin was 0.7 percentage points.
RESULTS: A total of 5429 patients underwent randomization. Venous thromboembolism developed in 13 of 2718 patients (0.48%) in the aspirin-alone group and in 12 of 2647 patients (0.45%) in the rivaroxaban-aspirin group (risk difference, 0.02 percentage points; 95% confidence interval [CI], -0.34 to 0.39; P<0.001 for noninferiority). Major bleeding or clinically relevant nonmajor bleeding events occurred in 45 of 2718 patients (1.66%) in the aspirin-alone group and in 54 of 2647 patients (2.04%) in the rivaroxaban-aspirin group (risk difference, -0.38%; 95% CI, -1.11 to 0.34).
CONCLUSIONS: After total hip and total knee arthroplasty, the use of aspirin alone was not inferior to a strategy of using rivaroxaban followed by aspirin for the prevention of symptomatic venous thromboembolism, with no clinically relevant difference in bleeding events. (Funded by the Canadian Institutes of Health Research; EPCAT III ClinicalTrials.gov number, NCT04075240.).
参考来源
- Shivakumar S, Matino D, Zukor D, et al. Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty. N Engl J Med. 2026. PMID: 42437501. doi:10.1056/NEJMoa2603649
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。